Warning: Attempt to assign property of non-object in /storage/content/87/218987/alligatorbioscience.se/public_html/wp-content/plugins/events-manager/classes/em-event.php on line 1091 Warning: Attempt to assign property of non-object in /storage/content/87/218987/alligatorbioscience.se/public_html/wp-content/plugins/events-manager/classes/em-event.php on line 1092

Strong pipeline

Warning: Attempt to assign property of non-object in /storage/content/87/218987/alligatorbioscience.se/public_html/wp-content/plugins/events-manager/classes/em-event.php on line 1091 Warning: Attempt to assign property of non-object in /storage/content/87/218987/alligatorbioscience.se/public_html/wp-content/plugins/events-manager/classes/em-event.php on line 1092
Warning: Attempt to assign property of non-object in /storage/content/87/218987/alligatorbioscience.se/public_html/wp-content/plugins/events-manager/classes/em-event.php on line 1091 Warning: Attempt to assign property of non-object in /storage/content/87/218987/alligatorbioscience.se/public_html/wp-content/plugins/events-manager/classes/em-event.php on line 1092

Alligator Bioscience has a broad project portfolio with several antibody-based immuno-oncology candidates. The company’s most advanced project, ADC-1013, in clinical Phase I being developed with partner Janssen Biotech, and the preclinical product candidates ATOR-1015, ATOR-1017, och ALG.APV-527.

Read more